Brief: Oxford Cannabinoid Says Results From Pre-Clinical Study Of OCT461201 Shows Positive Results

Oxford Cannabinoid Technologies Holdings

08/03/2022 20:33

March 8 (Reuters) - Oxford Cannabinoid Technologies Holdings
PLC  OCTP.L :
    * DATA FROM PRE-CLINICAL STUDY OF OCT461201 SHOWS POSITIVE
RESULTS
    * OXFORD CANNABINOID- RESULTS FROM RECENT STUDY SHOW THAT
OCT461201 SUCCESSFULLY REDUCES PAIN IN PRE-CLINICAL ANIMAL MODEL
OF CIPN INDUCED BY PACLITAXEL
    * OXFORD CANNABINOID - OCT461201 SIGNIFICANTLY REDUCED PAIN
FROM
BOTH MECHANICAL ALLODYNIA AND THERMAL HYPERALGESIA COMPARED TO
UNTREATED ANIMALS
    * OCT IS CONDUCTING PRE-CLINICAL TESTING AND DEVELOPMENT
WITH
CLINICAL TRIALS SCHEDULED FOR Q1 2023
    * CO'S CEO SAYS STARTING PHASE 1 CLINICAL TRIALS EARLY NEXT
YEAR

Source text for Eikon:  ID:nEQ7Gq423a 
Further company coverage:  OCTP.L 

 ((Reuters.Briefs@thomsonreuters.com;))